Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Aimmune Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Aimmune Therapeutics Inc market cap is $2.26B.
What is the 52-week high for Aimmune Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aimmune Therapeutics Inc 52 week high is $37.00 as of September 15, 2025.
What is the 52-week low for Aimmune Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aimmune Therapeutics Inc 52 week low is $10.09 as of September 15, 2025.
What is Aimmune Therapeutics Inc stock price today?
Aimmune Therapeutics Inc stock price today is $34.49.
What was Aimmune Therapeutics Inc stock price yesterday?
Aimmune Therapeutics Inc stock price yesterday was $34.59.
What is the PE ratio of Aimmune Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Aimmune Therapeutics Inc’s P/E ratio is -7.68.
What is the Price-to-Book ratio of Aimmune Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Aimmune Therapeutics Inc P/B ratio is 12.5489.
What is the 50-day moving average of Aimmune Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aimmune Therapeutics Inc 50-day moving average is $26.34.